Credit downgrades like this aren’t just bureaucratic noise—they can make it harder (and more expensive) for companies to borrow money. For Maravai, a biotech tools supplier, this signals deeper struggles, possibly from weaker demand or rising costs. If you’re in biotech or finance, this is a red flag worth watching.

S&P Global Ratings just downgraded Maravai LifeSciences' credit rating to 'B-', citing shrinking revenue and EBITDA (a key measure of profitability). Essentially, the company’s financial health is looking shaky, and investors are taking notice.

Maravai ratings drop to 'B-' at S&P due to decline in revenue and EBITDA

Was this article worth reading? Share it

Ready to build your own newsroom?